June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Viaual Outcomes Following Bevacizumab Treatment in Diabetic Macular Edema
Author Affiliations & Notes
  • jluwi almasaud
    king khaled eye special hospital, Riyadh, Saudi Arabia
  • Abdulrahman Alfaran
    king saud university, Riyadh, Saudi Arabia
  • Ahmed Mousa
    king saud university, Riyadh, Saudi Arabia
  • Nicola Ghazi
    king khaled eye special hospital, Riyadh, Saudi Arabia
  • Footnotes
    Commercial Relationships jluwi almasaud, None; Abdulrahman Alfaran, None; Ahmed Mousa, None; Nicola Ghazi, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2392. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      jluwi almasaud, Abdulrahman Alfaran, Ahmed Mousa, Nicola Ghazi; Viaual Outcomes Following Bevacizumab Treatment in Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2392.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: to study the visual outcomes following intravitreal bevacizumab treatment for eyes with center-involved diabetic macular edema (CIDME)

Methods: A retrospective study of 1000 eyes with CIDME that received intravitreal bevacizumab as their main treatment at the King Khaled Eye Specialist Hospital was performed. At each follow up visit, a full ophthalmic evaluation was performed. Fluorescein angiography was obtained as per physician’s preference. Statistical analysis comparing the final and baseline visual acuity was performed.

Results: Forty-nine eyes of 35 patients were analyzed at the time of this writing. Twenty-five patients (71.4%) were males and 10 (28.6%) were females with a mean age of 57.22 years (range 29 - 78 years; SD= 10.4). The baseline log MAR visual acuity ranged from 0.3 to 1.2 (mean ± SD= 0.53 ± 0.23) (20/40 to 20/300 Snellen equivalent range). The mean duration of follow-up was 13.6 months (range 6 - 36 months; SD= 7.6). Nineteen eyes (38.8%) had at least two lines of Snellen visual acuity improvement at final follow up.

Conclusions: Bevacizumab may improve vision in a substantial proportion of patients with CIDME. It may be an alternative to ranibizumab as a first line therapy for this condition.

Keywords: 748 vascular endothelial growth factor • 505 edema  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.